WG (n=24) | HC (n=24) | ||
---|---|---|---|
Sex, male | 13 | 12 | |
Age (years) | |||
Mean (SD) | 50.5 (10.0) | 49.4 (8.4) | |
Range | 27–64 | 25–63 | |
Influenza vaccination in previous year, n (%) | 12 (50)§ | 1 (4.2) | |
Without immunosuppressive drugs, n (%) | 13 (54.2) | NA | |
Duration* (months), median (range) | 39 (8–154) | NA | |
With immunosuppressive drugs, n (%) | 11 (45.8) | NA | |
Duration* (months), median (range) | 4 (2–20) | NA | |
Prednisone, n (%) | 8 (33.3) | NA | |
Median (range), in users (mg/day) | 5.63 (2.5–12.5) | ||
Azathioprine, n (%) | 8 (33.3) | NA | |
Median (range), in users (mg/day) | 100 (35.7†–150) | ||
Other immunosuppressive drugs, n (%) | 2 (8.3)‡ | NA | |
BVAS, median (range) | t = 0 | 0 (0–0) | NA |
↵* Duration: length of time without immunosuppressive drugs or length of time of stable use of current immunosuppressive drugs;
↵† one patient used azathioprine 50 mg five times a week;
↵‡ one patient used ciclosporin 125 mg/day and one patient used cyclophosphamide 25 mg/day, neither used any other immunosuppressive drug; §p<0.01.
BVAS, Birmingham Vasculitis Activity Score; HC, healthy controls; WG, Wegener's granulomatosis.